

Notice on the Establishment of Holding Company in Europe

February 7, 2012, Osaka Japan--Santen Pharmaceutical Co., Ltd. announced today that it will establish Santen Holdings EU B.V. ("Santen EU") in the Kingdom of Netherlands. Santen EU will be established as a holding company of Santen's existing subsidiaries in Europe, which will overlook Santen's European business.

Santen sets as its long term strategic vision, to become a "Specialty pharmaceutical company with a global presence" by year 2020. It also aims to expand its business in Europe, within its Medium-term Management Plan 2011-2013.

Based on such business strategies and plans, Santen aims to strengthen its European business by creating a more efficient and effective governance system by concentrating the financial control functions of Santen's European operation.

By strengthening its European business, Santen wishes to contribute in improving the QOL (Quality of Life) of patients and their loved ones all over the world.

Profile of Santen Holdings EU B.V.

Company name:	Santen Holdings EU B.V. (The company name is subject to confirmation by local authority.)
Location:	Amsterdam, Kingdom of the Netherlands
Paid-in capital:	Euro 50,000
Equity ownership:	100% by Santen Pharmaceutical Co., Ltd.
Representative:	Masamichi Sato
Purpose	Holding company for European operation

###